ADRB1

ADRB1 is a catecholamine-responsive G-protein-coupled receptor whose adrenergic signaling drives tissue-specific physiological programs, from cardiac stress responses to adipocyte thermogenesis and central reward processing (PMID:33372534, PMID:37857642, PMID:38970835). In cardiomyocytes, agonist-bound ADRB1 is engaged by GRK2 through a direct interaction that drives receptor internalization and epinephrine-induced expression of hypertrophic and fibrotic genes; depletion of GRK2 or pharmacological disruption of the GRK2-ADRB1 interaction by paroxetine prevents internalization and restores receptor sensitivity (PMID:33372534). ADRB1 abundance is constrained at multiple regulatory layers: miR-19a directly targets the ADRB1 3'UTR to repress expression (PMID:25785039), FTO-dependent removal of m6A marks on the ADRB1 transcript raises its expression (PMID:35904284), and promoter CpG methylation tunes ADRB1 levels across tissues (PMID:38970835). Functionally, FTO-driven ADRB1 inhibits adipocyte differentiation (PMID:35904284), while elevated ADRB1 promotes norepinephrine-induced browning of adipocytes through enhanced beige-fat marker expression and mitochondrial biogenesis (PMID:38970835). Common coding polymorphisms gate signaling output: the Arg389 variant is a gain-of-function allele conferring greater agonist-driven heart rate and renin responses to dobutamine and greater antagonist inhibition by esmolol (PMID:23114278, PMID:26313487). In the brain, ADRB1 on CaMKII-positive medial prefrontal cortex neurons mediates adrenergic neuronal activation and methamphetamine reward sensitization, with downstream p-ERK1/2 and ΔFosB signaling (PMID:37857642).

1. 2013 Medium

   Established that the common Arg389Gly coding variant alters the receptor's pharmacodynamic response to a β1AR antagonist in vivo, demonstrating that ADRB1 genotype shapes drug response.

   Evidence Randomized pharmacodynamic crossover study with esmolol infusion and exercise challenge in genotype-selected healthy volunteers

   PMID:23114278

   Open questions at the time

   • Does not resolve the molecular basis of the altered antagonist sensitivity at the receptor level
   • Limited to acute heart rate readout in healthy subjects
2. 2015 Medium

   Defined a post-transcriptional brake on ADRB1 by showing miR-19a directly represses the receptor via its 3'UTR, adding a layer of expression control beyond ligand-driven signaling.

   Evidence AGO2 knockdown, 3'UTR dual-luciferase reporter assay, and western blot

   PMID:25785039

   Open questions at the time

   • Physiological context where miR-19a regulates ADRB1 not defined
   • No in vivo validation of the repression
3. 2015 Medium

   Extended the Arg389Gly variant's impact to agonist signaling, establishing Arg389 as a gain-of-function allele for both chronotropic and renin responses.

   Evidence Controlled dobutamine infusion in genotype-selected individuals with heart rate, blood pressure, and plasma renin measurements

   PMID:26313487

   Open questions at the time

   • Receptor-level mechanism of enhanced signaling not directly measured
   • Effect sizes from healthy subjects may not translate to disease states
4. 2020 High

   Identified GRK2 as a direct ADRB1 interactor controlling receptor internalization and pathological cardiac gene expression, and showed paroxetine can pharmacologically block this interaction to preserve receptor sensitivity.

   Evidence Co-immunoprecipitation, GRK2 genetic knockdown, in vitro cardiomyocyte assays, and an in vivo spontaneously hypertensive rat model

   PMID:33372534

   Open questions at the time

   • Structural basis of the GRK2-ADRB1 interface not resolved
   • Whether paroxetine's effect is specific to cardiac contexts not established
5. 2022 Medium

   Linked m6A epigenetic marking to ADRB1 expression by showing FTO demethylase activity raises ADRB1 mRNA, and placed ADRB1 as a brake on adipocyte differentiation.

   Evidence siRNA knockdown of FTO and ADRB1, MeRIP-qPCR for m6A, oil red O staining, and triglyceride assays in rabbit preadipocytes

   PMID:35904284

   Open questions at the time

   • Specific m6A reader interpreting the mark on ADRB1 mRNA not identified
   • Demonstrated in rabbit cells; human relevance not tested
6. 2023 Medium

   Assigned a central nervous system role to ADRB1 by showing receptor on CaMKII+ mPFC neurons mediates methamphetamine reward sensitization through adrenergic neuronal activation.

   Evidence Conditioned place preference, betaxolol microinfusion, viral knockdown of ADRB1 in CaMKII+ neurons, and neuronal activity recording in METH-sired offspring

   PMID:37857642

   Open questions at the time

   • Causal role of p-ERK1/2 and ΔFosB downstream signals not definitively established
   • Restricted to a paternal methamphetamine-exposure model
7. 2024 Medium

   Connected promoter CpG methylation to ADRB1 expression differences and demonstrated ADRB1 promotes norepinephrine-induced adipocyte browning, framing it as an effector of thermogenic adaptation.

   Evidence Promoter methylation analysis, ADRB1 overexpression and antagonist treatment, beige-fat marker and mitochondrial biogenesis readouts in Min vs. DLY pig adipocytes

   PMID:38970835

   Open questions at the time

   • Mechanism coupling ADRB1 signaling to mitochondrial biogenesis not detailed
   • Demonstrated in pig adipocytes
8. 2025 Low

   Proposed an atomic mechanism for ADRB1 activation in which water-mediated networks and sodium/protonation microswitches enable agonist-driven conformational transitions.

   Evidence Multi-replica OneOPES enhanced sampling molecular dynamics of apo and adrenaline-bound ADRB1 (preprint)

   Open questions at the time

   • Computational prediction only, no experimental validation reported
   • Functional consequences of the proposed microswitches not tested
9. 2025 Medium

   Identified ADRB1 as a candidate autoantigen by showing CD4+ T cells recognize an ADRB1 peptide on HLA-DRB1*13 with a memory phenotype enriched in myocardial infarction patients.

   Evidence Peptide stimulation of PBMCs, single-cell RNA/TCR-seq, HLA-tetramer staining, and reporter cell TCR validation (preprint)

   Open questions at the time

   • Causal contribution of ADRB1-specific T cells to cardiovascular disease not established
   • Preprint, single group
10. 2025 Medium

    Linked ADRB1/ADRB2 N-terminus internalization haplotypes to biased-ligand therapeutic response, proposing an internalization-associated cardioprotective ERK1/2 pathway selectively engaged by bucindolol.

    Evidence Clinical trial genetic substudy with Cox regression and ERK1/2 activation in isolated human ventricular preparations (preprint)

    Open questions at the time

    • Mechanistic link between internalization resistance and ERK1/2 activation not fully defined
    • Preprint, single group

• How the diverse regulatory inputs on ADRB1 (GRK2 internalization, miRNA and m6A control, promoter methylation, biased-ligand signaling) are integrated within a single cell type to determine receptor output remains unresolved.
• No unified model coupling expression control to signaling bias
• Tissue-specific integration of these layers not characterized